tiprankstipranks
Advertisement
Advertisement

MDGL Stock Latest News

Madrigal’s Rezdiffra Drives Blockbuster Growth Amid Costs
Company AnnouncementsMadrigal’s Rezdiffra Drives Blockbuster Growth Amid Costs
23h ago
MDGL
Paulson takes new stake in Amicus, cuts position in Madrigal Pharma
PremiumThe Fly
Paulson takes new stake in Amicus, cuts position in Madrigal Pharma
5d ago
BHC
Madrigal Pharmaceuticals price target raised to $709 from $640 at Truist
PremiumThe Fly
Madrigal Pharmaceuticals price target raised to $709 from $640 at Truist
8d ago
MDGL
Madrigal Pharmaceuticals price target lowered to $578 from $587 at Canaccord
PremiumThe Fly
Madrigal Pharmaceuticals price target lowered to $578 from $587 at Canaccord
13d ago
MDGL
Madrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISI
PremiumThe Fly
Madrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISI
14d ago
MDGL
Madrigal Pharmaceuticals reports Q1 EPS ($3.25), consensus ($4.14)
PremiumThe FlyMadrigal Pharmaceuticals reports Q1 EPS ($3.25), consensus ($4.14)
14d ago
MDGL
Madrigal Earnings Call: Rezdiffra Boom, Profits Delayed
Premium
Company Announcements
Madrigal Earnings Call: Rezdiffra Boom, Profits Delayed
14d ago
MDGL
Madrigal Pharmaceuticals price target raised to $680 from $533 at Clear Street
Premium
The Fly
Madrigal Pharmaceuticals price target raised to $680 from $533 at Clear Street
14d ago
MDGL
Arrowhead announces exclusive worldwide license agreement with Madrigal Pharma
PremiumThe Fly
Arrowhead announces exclusive worldwide license agreement with Madrigal Pharma
16d ago
ARWR
MDGL
MDGL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
MDGL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
17d ago
MDGL
Madrigal Expands Resmetirom Reach With New Post-Transplant MASH Trial
PremiumCompany Announcements
Madrigal Expands Resmetirom Reach With New Post-Transplant MASH Trial
20d ago
MDGL
Madrigal Pharmaceuticals Reclassifies Board Ahead of 2026 Meeting
PremiumCompany Announcements
Madrigal Pharmaceuticals Reclassifies Board Ahead of 2026 Meeting
22d ago
8K
MDGL
Ritu Baral Reaffirms Buy on Madrigal Pharmaceuticals Following Updated Financial Model and Sustained Long-Term Upside Outlook
PremiumRatingsRitu Baral Reaffirms Buy on Madrigal Pharmaceuticals Following Updated Financial Model and Sustained Long-Term Upside Outlook
28d ago
MDGL
Madrigal Pharmaceuticals off highs, remains up 13% in afternoon trading
Premium
The Fly
Madrigal Pharmaceuticals off highs, remains up 13% in afternoon trading
2M ago
MDGL
Madrigal’s Rezdiffra Drives Blockbuster‑Level First Year
Premium
Company Announcements
Madrigal’s Rezdiffra Drives Blockbuster‑Level First Year
3M ago
MDGL
Madrigal Pharmaceuticals price target lowered to $529 from $570 at BofA
PremiumThe Fly
Madrigal Pharmaceuticals price target lowered to $529 from $570 at BofA
3M ago
MDGL
Madrigal Pharmaceuticals: Rezdiffra’s Strong Launch, Expanding Prescriber Adoption, and Advancing Pipeline Underpin Buy Rating
PremiumRatings
Madrigal Pharmaceuticals: Rezdiffra’s Strong Launch, Expanding Prescriber Adoption, and Advancing Pipeline Underpin Buy Rating
3M ago
MDGL
Madrigal Pharmaceuticals reports Q4 EPS ($2.57), consensus (88c)
PremiumThe Fly
Madrigal Pharmaceuticals reports Q4 EPS ($2.57), consensus (88c)
3M ago
MDGL
Paulson buys Solstice, exits Honeywell in Q4
PremiumThe Fly
Paulson buys Solstice, exits Honeywell in Q4
3M ago
BHC
MDGL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsMDGL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
MDGL
Madrigal Pharmaceuticals announces exclusive license pact with Suzho Ribo
Premium
The Fly
Madrigal Pharmaceuticals announces exclusive license pact with Suzho Ribo
3M ago
MDGL
Madrigal Pharmaceuticals price target lowered to $570 from $595 at BofA
Premium
The Fly
Madrigal Pharmaceuticals price target lowered to $570 from $595 at BofA
4M ago
MDGL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >